Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Scinai Immunotherapeutics (Nasdaq: SCNI) has appointed Prof. Michael Schön to its Scientific Advisory Board. Prof. Schön is currently the Director of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen and serves as Vice Dean and Deputy Director for Research and Teaching. He brings extensive expertise in dermatology and immunology, with over 440 scientific publications and significant experience in treating inflammatory skin diseases.
Prof. Schön expressed enthusiasm about contributing to Scinai's innovative pipeline, particularly in addressing unmet medical needs in chronic inflammatory skin diseases. The company's CEO, Amir Reichman, highlighted Prof. Schön's expertise in psoriasis and atopic dermatitis as valuable assets for advancing Scinai's inflammation and immunology biological products pipeline.
Scinai Immunotherapeutics (Nasdaq: SCNI) ha nominato Prof. Michael Schön nel suo Comitato Scientifico. Il Prof. Schön è attualmente Direttore di Dermatologia, Venereologia e Allergologia presso l'Università Medica di Göttingen e ricopre inoltre il ruolo di Vice Decano e Direttore Adjoint per la Ricerca e l'Insegnamento. Porta con sé un'ampia esperienza in dermatologia e immunologia, con oltre 440 pubblicazioni scientifiche e una notevole esperienza nel trattare le malattie infiammatorie della pelle.
Il Prof. Schön ha espresso entusiasmo nel contribuire alla pipeline innovativa di Scinai, in particolare per affrontare le necessità mediche insoddisfatte nelle malattie infiammatorie croniche della pelle. Il CEO dell'azienda, Amir Reichman, ha sottolineato l'esperienza del Prof. Schön nella psoriasi e nella dermatite atopica come risorse preziose per far avanzare la pipeline dei prodotti biologici per l'infiammazione e l'immunologia di Scinai.
Scinai Immunotherapeutics (Nasdaq: SCNI) ha nombrado al Prof. Michael Schön en su Consejo Asesor Científico. El Prof. Schön es actualmente Director de Dermatología, Venereología y Alergología en el Centro Médico Universitario de Göttingen y también se desempeña como Vice Decano y Director Adjunto de Investigación y Docencia. Aporta una amplia experiencia en dermatología e inmunología, con más de 440 publicaciones científicas y una vasta experiencia en el tratamiento de enfermedades inflamatorias de la piel.
El Prof. Schön expresó su entusiasmo por contribuir a la innovadora línea de productos de Scinai, especialmente en la atención de necesidades médicas no satisfechas en enfermedades crónicas inflamatorias de la piel. El CEO de la empresa, Amir Reichman, destacó la experiencia del Prof. Schön en psoriasis y dermatitis atópica como activos valiosos para el avance de la línea de productos biológicos de inflamación e inmunología de Scinai.
Scinai Immunotherapeutics (Nasdaq: SCNI)는 Prof. Michael Schön을 과학 자문 위원회에 임명했습니다. Schön 교수는 현재 괴팅겐 대학병원에서 피부과, 성병과 및 알레르기학 부장으로 재직하고 있으며, 연구 및 교육을 위한 부학장으로도 활동하고 있습니다. 그는 피부과 및 면역학 분야에서 440편 이상의 과학 논문을 발표한 풍부한 경험을 가지고 있으며, 염증성 피부 질환 치료에 대한 중요한 경험을 보유하고 있습니다.
Schön 교수는 Scinai의 혁신적인 파이프라인에 기여하게 되어 매우 기쁘다고 밝혔으며, 특히 만성 염증성 피부 질환에서 충족되지 않은 의료 필요를 해결하는 데 집중하고 있습니다. 회사의 CEO인 Amir Reichman은 Schön 교수의 건선 및 아토피 피부염에 대한 전문 지식이 Scinai의 염증 및 면역 생물학 제품 파이프라인을 발전시키는 데 매우 귀중한 자산이라고 강조했습니다.
Scinai Immunotherapeutics (Nasdaq: SCNI) a nommé Prof. Michael Schön au sein de son Conseil Consultatif Scientifique. Le Prof. Schön est actuellement directeur de la Dermatologie, Vénérologie et Allergologie au Centre Médical Universitaire de Göttingen et occupe également le poste de vice-doyen et de directeur adjoint de la Recherche et de l'Enseignement. Il apporte une vaste expertise en dermatologie et immunologie, avec plus de 440 publications scientifiques et une expérience significative dans le traitement des maladies inflammatoires de la peau.
Le Prof. Schön a exprimé son enthousiasme à contribuer à la pipeline innovante de Scinai, en particulier concernant les besoins médicaux non satisfaits dans les maladies cutanées inflammatoires chroniques. Le PDG de l'entreprise, Amir Reichman, a souligné que l'expertise du Prof. Schön en matière de psoriasis et de dermatite atopique constituait des atouts précieux pour faire avancer la pipeline des produits biologiques de Scinai dans le domaine de l'inflammation et de l'immunologie.
Scinai Immunotherapeutics (Nasdaq: SCNI) hat Prof. Michael Schön in seinen Wissenschaftlichen Beirat berufen. Prof. Schön ist derzeit Direktor für Dermatologie, Venerologie und Allergologie am Universitätsmedizin Göttingen und fungiert als Vize-Dekan sowie stellvertretender Direktor für Forschung und Lehre. Er bringt umfassende Expertise in Dermatologie und Immunologie mit, sowie über 440 wissenschaftliche Publikationen und bedeutende Erfahrungen in der Behandlung entzündlicher Hauterkrankungen.
Prof. Schön äußerte sich begeistert über seinen Beitrag zur innovativen Pipeline von Scinai, insbesondere in Bezug auf die nicht erfüllten medizinischen Bedürfnisse bei chronischen entzündlichen Hauterkrankungen. Der CEO des Unternehmens, Amir Reichman, hob die Expertise von Prof. Schön in Bezug auf Psoriasis und atopische Dermatitis als wertvolle Ressourcen für den Fortschritt der biologischen Produkte von Scinai im Bereich Entzündung und Immunologie hervor.
- Addition of a world-class expert in dermatology and immunology to the Scientific Advisory Board
- Prof. Schön brings extensive research experience with over 440 scientific publications
- Strengthens company's expertise in key therapeutic areas (psoriasis and atopic dermatitis)
- None.
Prof. Michael Schön is a distinguished Professor and Director of the Department of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen. He also serves as Vice Dean and Deputy Director for Research and Teaching and is the former director of the Lower Saxony Institute of Occupational Dermatology. Prof. Schön has been recognized with numerous awards for his groundbreaking research on immune reactions in inflammation. From 2011 to 2024, he was the Editor-in-Chief of the Journal of the German Dermatological Society. Currently, he holds the position of Secretary General and Vice President of the European Dermatology Forum (EDF).
Prof. Schön earned his MD in Medicine from the University of Ulm,
Prof. Schön commented: "It is a great pleasure and honor for me to be part of the advisory board for Scinai and to contribute to the success of their highly innovative pipeline. In many areas of chronic inflammatory skin diseases, but also in other organ systems with immunologically mediated diseases, there is a significant unmet medical need. In my view, Scinai's targeted immunological therapeutic approaches have excellent potential to provide exciting innovation in various areas of precision inflammation medicine."
Amir Reichman, CEO of Scinai, stated: "We are thrilled to welcome Prof. Schön, a world-class expert in dermatology, particularly in psoriasis and atopic dermatitis, to our Scientific Advisory Board. Michael's extensive experience as a dermatologist, having treated thousands of patients, and as a researcher with over 440 scientific publications in top-rated journals, along with his proven track record in drug development and clinical research, will be invaluable to Scinai. His insights will be crucial as we advance our pipeline of innovative I&I biological products. Additionally, I would like to congratulate Dr. Jonathan Sadeh, a member of our Scientific Advisory Board, on his recent appointment as Chief Scientific Officer and Chief Medical Officer of Bausch Health. We wish Jonathan great success in his new role. These two recent appointments to our Scientific Advisory Board are a testament to the high caliber of talent advising our R&D team and board of directors."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, the potential of Scinai's NanoAb program and the advancement of its pipeline of innovative I&I biological products. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will not successfully advance its pipeline of innovative I&I biological products; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Photo - https://mma.prnewswire.com/media/2574354/Scinai_Immunotherapeutics.jpg
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/prof-michael-schon-director-of-dermatology-and-venereology-at-the-university-medical-center-gottingen-germany-umg-joins-scinai-immunotherapeutics-scientific-advisory-board-302323843.html
SOURCE Scinai Immunotherapeutics Ltd.
FAQ
Who is the newest member of Scinai Immunotherapeutics' (SCNI) Scientific Advisory Board?
What is Prof. Schön's expertise in relation to Scinai Immunotherapeutics (SCNI)?
How will Prof. Schön's appointment benefit Scinai Immunotherapeutics (SCNI)?
